EL COMITE DE PRÁCTICAS DE LA INMUNIZACIÓN DE LOS EEUU RECOMIENDA LA VACUNA NEUMOCOCO 13 A LOS ADULTOS DE RIESGO Y MAYORES

 

LA VACUNA CONTRA EL NEUMOCOCO 13 ES RECOMENDADA PARA LOS ADULTOS CON ALTO RIESGO Y ADULTOS MAYORES EN RIESGO, ES INTERESANTE LA EVOLUCIÓN DE ESTA IMPORTANTE VBACUNA QUE DISMINUYE LA ENFERMEDAD EN LOS PROTEGIDOS Y SU ENTORNO CUANDO SE USA EN ALTAS COBERTURAS.

ABAJO LOS DETALLES,

 

Compartiendo con amigos en el pasado Congreso Nacional de Pediatría Septiembre 2012

SALUD,

This message serves to inform you about the new ACIP recommendations to give PCV13 (Prevnar 13) to high-risk adults and includes reviews on existing PPSV23 (Pneumovax) recommendations for adults.

Now on Medscape, CDC expert Tamara Pilishvili, MPH, talks about the new Advisory Committee on Immunization Practices (ACIP) recommendations to give PCV13 (Prevnar 13) to high-risk adults and reviews existing PPSV23 (Pneumovax) recommendations for adults. This overview is a must-see for every doctor, nurse, and health care provider who provides medical care to adults.

Healthcare providers should follow these overarching recommendations:

• Adults 19 years of age or older with immunocompromising conditions, functional or anatomic asplenia, CSF leaks, or cochlear implants, and who have not previously received PCV13 or PPSV23, should receive a dose of PCV13 first followed by a dose of PPSV23 at least 8 weeks later. Subsequent doses of PPSV23 should follow current PPSV23 recommendations for high risk adults.
• Adults 19 years of age or older with the aforementioned conditions (functional or anatomic asplenia, immunocompromising conditions, or those with CSF leaks or cochlear implants) who have previously received one or more doses of PPSV23 should be given a dose of PCV13 one or more years after the last PPSV23 dose was received. For those who require additional doses of PPSV23, the first such dose should be given no sooner than 8 weeks after PCV13 and at least 5 years since the most recent dose of PPSV23.
• Those who received one or more doses of PPSV23 before age 65 years for any indication should receive another dose of the vaccine at age 65 years or older if at least 5 years have elapsed since their previous PPSV23 dose. If a dose of PPSV23 was received at age 65 years or later, no additional doses of PPSV23 are recommended.
• PPSV23 recommendations remain the same for those 65 years and older and those who are immunocompetent with chronic medical conditions, such as diabetes or heart disease.

To learn more about pneumococcal disease and vaccines, visit the resources listed below.

Web Sites

• Pneumococcal vaccine resources
• Recommendations, scenarios and Q&As for health care professionals about PCV13 for immunocompromised adults
• Table: Medical conditions or other indications for administration of PCV13, and indications for PPSV23 administration and revaccination for adults 19 years of age or older

ACIP Recommendations

• Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
• Updated Recommendations for Prevention of Invasive Pneumococcal Disease Among Adults Using the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23)

Video

• CDC Medscape Commentary: Latest Adult Pneumococcal Vaccine Recommendations by Tamara Pilishvili, MPH